Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.
The ONCT news page on Stock Titan aggregates press releases and other coverage related to Oncternal Therapeutics, Inc., a company that has been described in its own communications as a clinical-stage biopharmaceutical developer of oncology therapies. These news items trace both the evolution of its investigational pipeline and its later strategic decisions, giving investors and researchers a consolidated view of the company’s trajectory.
Earlier news focuses on clinical and operational updates for programs such as ONCT-534, an investigational dual-action androgen receptor inhibitor evaluated in metastatic castration-resistant prostate cancer, and ONCT-808, an autologous CAR T cell therapy targeting ROR1 in relapsed or refractory aggressive B-cell lymphoma. Releases detail dose-escalation cohorts, safety and tolerability observations, interim efficacy signals based on measures like prostate-specific antigen levels, and protocol amendments in ongoing Phase 1/2 studies.
Other articles describe the broader pipeline, including zilovertamab, a monoclonal antibody targeting ROR1 studied in combination with ibrutinib and in investigator-initiated trials, and ONCT-216, a small-molecule inhibitor of ETS family oncoproteins with regulatory designations for Ewing sarcoma. These pieces provide context on the scientific rationale and clinical settings in which the agents have been tested.
More recent news documents a shift in corporate direction. A September 2024 press release announces the termination of clinical studies for ONCT-534 and ONCT-808, the discontinuation of product development activities and the exploration of strategic alternatives. A July 2025 release reports the sale of the zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc. and states that a new executive will oversee the winddown of Oncternal’s operations. Together, these items form a historical record of how the ONCT story moved from active clinical development toward asset sales and an operational wind-down.
Users interested in ONCT news can review this stream to understand the company’s investigational programs, clinical milestones, strategic reviews and the subsequent wind-down steps described by Oncternal in its own announcements.
Oncternal Therapeutics (Nasdaq: ONCT) has announced its participation in the Jefferies Healthcare Conference from June 8-10, 2022. The company's CEO, James Breitmeyer, will present a corporate overview on June 8th at 9:30 AM ET, and one-on-one meetings will be available.
The company focuses on developing innovative oncology therapies, with lead programs targeting ROR1 through investigational drugs like zilovertamab and ONCT-808. For more information, visit oncternal.com.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced the granting of an inducement award to new Head of Clinical Science, Ted Shih, on June 1, 2022. This award, part of the 2021 Employment Inducement Incentive Award Plan, includes an option to purchase 70,000 shares of common stock, vesting over four years. The approval came from Oncternal’s independent compensation committee, ensuring compliance with Nasdaq rules. Oncternal focuses on developing therapies for cancers with significant unmet medical needs, including ongoing clinical trials for its lead product, zilovertamab.
Oncternal Therapeutics announced updated interim data from the Phase 1/2 CIRLL study evaluating zilovertamab combined with ibrutinib for treating mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). The overall response rate (ORR) for MCL was 85%, significantly outperforming historical data. For CLL, the ORR reached 91%, with a landmark progression-free survival (PFS) of 100% at 36 months for patients with specific prior therapies. Zilovertamab, targeting ROR1, showed a favorable safety profile, enhancing the company's confidence in moving towards a Phase 3 trial.
Oncternal Therapeutics (Nasdaq: ONCT) reported a robust business update on May 5, 2022, highlighting the upcoming initiation of the global Phase 3 study ZILO-301 for zilovertamab, targeting mantle cell lymphoma (MCL) in Q3 2022. The company plans to present interim data at ASCO 2022 for ongoing trials. A strategic partnership with Dana-Farber Cancer Institute was established to support CAR-T cell therapy ONCT-808. Moreover, ONCT-216 development was deprioritized, extending cash runway to Q3 2023 with $82.2 million in cash. The net loss for Q1 2022 was $9.9 million, or $0.20 per share.
Oncternal Therapeutics (Nasdaq: ONCT) announced the granting of an inducement award to new Clinical Data Manager, Samantha Carrington, on May 2, 2022. The award includes an option to purchase 20,000 shares of common stock, with a ten-year term and an exercise price based on the closing stock price on the grant date. The option vests over four years, with an initial 25% vesting after one year, followed by monthly installments. This award complies with Nasdaq's rules and aims to incentivize employees to join the company.
Oncternal Therapeutics (Nasdaq: ONCT) announced it will report its first quarter 2022 financial results on May 5, 2022, after market close. The management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss these results and provide a comprehensive business update. Oncternal focuses on developing innovative oncology therapies targeting unmet medical needs, particularly in hematological malignancies and prostate cancer. Its clinical pipeline includes therapies such as zilovertamab and ONCT-808.
Oncternal Therapeutics (ONCT) announced the discontinuation of enrollment in the Phase 1/2 trial of ONCT-216 for Ewing sarcoma. The company is reallocating resources to focus on zilovertamab's Phase 3 study (ZILO-301), expected to start in Q3 2022, targeting mantle cell lymphoma (MCL). Oncternal also plans to submit an IND for its ROR1-targeting CAR-T therapy, ONCT-808, in mid-2022, alongside advancing the ONCT-534 program. With approximately $82.2 million in cash and no debt, the company expects to fund operations into Q3 2023.
Oncternal Therapeutics (Nasdaq: ONCT) announced the grant of an inducement award to Rachel Monet Kenny, the new Associate Director, CMC and Clinical Supply Chain, on April 1, 2022. The award includes an option to purchase 28,400 shares of common stock, vesting over four years. This move aligns with Nasdaq rules for employee incentives and aims to attract talent to support Oncternal’s focus on oncology therapies targeting unmet medical needs. The company continues to develop promising therapies like zilovertamab and ONCT-808 for various cancer treatments.
Oncternal Therapeutics announced progress in multiple clinical programs, including the Phase 3 Study ZILO-301 for treating relapsed or refractory mantle cell lymphoma (MCL) with zilovertamab and ibrutinib. Interim results exhibit an 81% objective response rate and a 35% complete response rate. The company also advanced ONCT-808 and ONCT-534 toward Investigational New Drug (IND) submissions. Financially, Oncternal reported a 2021 net loss of $31.3 million but maintains a robust cash position of $90.8 million, expected to sustain operations into mid-2023.
Oncternal Therapeutics (Nasdaq: ONCT) will release its Fourth Quarter and Full Year 2021 financial results on March 10, 2022, after U.S. markets close. A management webcast will follow at 2:00 p.m. PT (5:00 p.m. ET) to discuss the results and provide a business update. The company is focused on developing oncology therapies for critical unmet medical needs and has a promising clinical pipeline, including zilovertamab and ONCT-808, targeting various cancers. Details are available at their investor website.